Literature DB >> 32275755

Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia.

Cassidy L Moody1, Adam J Funk2, Emily Devine2, Ryan C Devore Homan2, Detlev Boison3, Robert E McCullumsmith2, Sinead M O'Donovan2.   

Abstract

The adenosine hypothesis of schizophrenia posits that reduced availability of the neuromodulator adenosine contributes to dysregulation of dopamine and glutamate transmission and the symptoms associated with schizophrenia. It has been proposed that increased expression of the enzyme adenosine kinase (ADK) may drive hypofunction of the adenosine system. While animal models of ADK overexpression support such a role for altered ADK, the expression of ADK in schizophrenia has yet to be examined. In this study, we assayed ADK gene and protein expression in frontocortical tissue from schizophrenia subjects. In the dorsolateral prefrontal cortex (DLPFC), ADK-long and -short splice variant expression was not significantly altered in schizophrenia compared to controls. There was also no significant difference in ADK splice variant expression in the frontal cortex of rats treated chronically with haloperidol-decanoate, in a study to identify the effect of antipsychotics on ADK gene expression. ADK protein expression was not significantly altered in the DLPFC or anterior cingulate cortex (ACC). There was no significant effect of antipsychotic medication on ADK protein expression in the DLPFC or ACC. Overall, our results suggest that increased ADK expression does not contribute to hypofunction of the adenosine system in schizophrenia and that alternative mechanisms are involved in dysregulation of this system in schizophrenia.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ACC; DLPFC; neuropsychiatric; postmortem

Mesh:

Substances:

Year:  2020        PMID: 32275755      PMCID: PMC7147579          DOI: 10.1093/schbul/sbz086

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  46 in total

1.  Possible case of allopurinol causing relapse of psychosis.

Authors:  Richard Gomberg
Journal:  Schizophr Res       Date:  2007-03-27       Impact factor: 4.939

2.  High-resolution copy number variation analysis of schizophrenia in Japan.

Authors:  I Kushima; B Aleksic; M Nakatochi; T Shimamura; T Shiino; A Yoshimi; H Kimura; Y Takasaki; C Wang; J Xing; K Ishizuka; T Oya-Ito; Y Nakamura; Y Arioka; T Maeda; M Yamamoto; M Yoshida; H Noma; S Hamada; M Morikawa; Y Uno; T Okada; T Iidaka; S Iritani; T Yamamoto; M Miyashita; A Kobori; M Arai; M Itokawa; M-C Cheng; Y-A Chuang; C-H Chen; M Suzuki; T Takahashi; R Hashimoto; H Yamamori; Y Yasuda; Y Watanabe; A Nunokawa; T Someya; M Ikeda; T Toyota; T Yoshikawa; S Numata; T Ohmori; S Kunimoto; D Mori; N Iwata; N Ozaki
Journal:  Mol Psychiatry       Date:  2016-05-31       Impact factor: 15.992

3.  A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia.

Authors:  Miriam G Brunstein; Eduardo S Ghisolfi; Fernanda L P Ramos; Diogo R Lara
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

4.  Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis".

Authors:  Elisabet Aliagas; Izaskun Villar-Menéndez; Jean Sévigny; Mercedes Roca; Miriam Romeu; Isidre Ferrer; Mireia Martín-Satué; Marta Barrachina
Journal:  Purinergic Signal       Date:  2013-06-16       Impact factor: 3.765

5.  Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs.

Authors:  Benjamin K Yee; Philipp Singer; Jiang-Fan Chen; Joram Feldon; Detlev Boison
Journal:  Eur J Neurosci       Date:  2007-11-14       Impact factor: 3.386

6.  The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers.

Authors:  Sanghyeon Kim; Maree J Webster
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?

Authors:  R E McCullumsmith; S M O'Donovan; J B Drummond; F S Benesh; M Simmons; R Roberts; T Lauriat; V Haroutunian; J H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2015-09-29       Impact factor: 15.992

8.  Adenosine kinase deficiency: expanding the clinical spectrum and evaluating therapeutic options.

Authors:  Christian Staufner; Martin Lindner; Carlo Dionisi-Vici; Peter Freisinger; Dries Dobbelaere; Claire Douillard; Nawal Makhseed; Beate K Straub; Kimia Kahrizi; Diana Ballhausen; Giancarlo la Marca; Stefan Kölker; Dorothea Haas; Georg F Hoffmann; Sarah C Grünert; Henk J Blom
Journal:  J Inherit Metab Dis       Date:  2015-12-07       Impact factor: 4.982

9.  An online database for brain disease research.

Authors:  Brandon W Higgs; Michael Elashoff; Sam Richman; Beata Barci
Journal:  BMC Genomics       Date:  2006-04-04       Impact factor: 3.969

10.  The global prevalence of schizophrenia.

Authors:  Dinesh Bhugra
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

View more
  2 in total

Review 1.  Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.

Authors:  Silvia Pasquini; Chiara Contri; Stefania Merighi; Stefania Gessi; Pier Andrea Borea; Katia Varani; Fabrizio Vincenzi
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 2.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.